Skip to main content
REGN
NASDAQ Life Sciences

杜必妥销售额飙升30.8%，在赛诺菲Q1报告中超出预期

feedReported by Reuters
Sentiment info
Positive
Importance info
7
Price
$745.79
Mkt Cap
$78.915B
52W Low
$476.487
52W High
$821.11
Market data snapshot near publication time

summarizeSummary

赛诺菲报告的第一季度收益略高于预期，得益于其重磅药物杜必妥的强劲需求。由赛诺菲与Regeneron合作开发的杜必妥销售额以恒定汇率计算，激增30.8%至417亿欧元（48.8亿美元），轻松超出分析师预期的389亿欧元。杜必妥的这一积极销售表现是在最近获得欧盟和FDA对该药物在新适应症的批准之后，强化了其强劲的增长轨迹。这一超出预期的销售额对Regeneron来说是一个重要的积极指标，因为杜必妥是该公司的关键收入驱动因素。投资者将监测杜必妥和Regeneron即将发布的收益报告中的未来销售趋势，以获取更多关于其收入份额的详细信息。

在该公告发布时，REGN的交易价格为$745.79，交易所为NASDAQ，所属行业为Life Sciences，市值约为$789.2亿。 52周交易区间为$476.49至$821.11。 这则新闻被评估为积极市场情绪，重要性评分为7/10。 来源：Reuters。

show_chartPrice Chart

Share this article

Copied!

feed REGN - Latest Insights

REGN
Apr 29, 2026, 6:54 AM EDT
Filing Type: 10-Q
Importance Score:
8
Regeneron Reports Mixed Q1 Results, Authorizes $3B Buyback, Details Government Pricing Deals & Key Legal Updates
Sentiment: Neutral
View Wiseek Article
REGN
Apr 29, 2026, 6:50 AM EDT
Filing Type: 8-K
Importance Score:
8
Regeneron Reports Strong Q1 Results, Authorizes New $3.0 Billion Share Repurchase, and Secures Strategic Government Pricing Agreement
Sentiment: Positive
View Wiseek Article
REGN
Apr 29, 2026, 6:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
Regeneron Posts 19% Revenue Growth in Q1, Non-GAAP EPS Up 15% Amidst GAAP Decline
Sentiment: Positive
View Wiseek Article
REGN
Apr 24, 2026, 12:25 AM EDT
Source: dpa-AFX
Importance Score:
8
Regeneron's Otarmeni Gene Therapy Approved by FDA for Genetic Hearing Loss
Sentiment: Positive
View Wiseek Article
REGN
Apr 23, 2026, 12:42 PM EDT
Source: Reuters
Importance Score:
8
FDA Approves Regeneron's Gene Therapy for Inherited Deafness
Sentiment: Positive
View Wiseek Article
REGN
Apr 23, 2026, 1:30 AM EDT
Source: Reuters
Importance Score:
7
Dupixent Sales Soar 30.8%, Beating Estimates in Sanofi's Q1 Report
Sentiment: Positive
View Wiseek Article
REGN
Apr 22, 2026, 5:30 PM EDT
Source: GlobeNewswire
Importance Score:
8
Dupixent Gains U.S. Approval for Young Children with Chronic Spontaneous Urticaria
Sentiment: Positive
View Wiseek Article
REGN
Apr 21, 2026, 10:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
Regeneron's Cemdisiran Phase 3 Data Published, Regulatory Filing Submitted for gMG
Sentiment: Positive
View Wiseek Article
REGN
Apr 13, 2026, 1:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Dupixent Secures EU Approval for Young Children with Chronic Urticaria, Expanding Key Market
Sentiment: Positive
View Wiseek Article
REGN
Apr 12, 2026, 7:08 PM EDT
Source: Dow Jones Newswires
Importance Score:
8
Regeneron Forms Radiopharma Partnership with Telix, Potentially Worth Over $2.1 Billion
Sentiment: Positive
View Wiseek Article